5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment (Q28269736)

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.

Europe PubMed Central

title

5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment (English)

0 references

author name string

Matti Aapro

series ordinal

1

0 references

language of work or name

English

0 references

publication date

2005

0 references

published in

Oncology

0 references

volume

69

0 references

issue

2

0 references

page(s)

97-109

0 references

cites work

1 reference

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

21 January 2018

1 reference

The analgesic efficacy of tramadol is impaired by concurrent administration of ondansetron

21 January 2018

1 reference

Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics

21 January 2018

1 reference

Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects

21 January 2018

1 reference

Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes

21 January 2018

1 reference

QT Prolongation and Fatal Arrhythmias: A Review of Clinical Implications and Effects of Drugs

21 January 2018

1 reference

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

21 January 2018

1 reference

Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy

21 January 2018

1 reference

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.

21 January 2018

1 reference

Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy

21 January 2018

1 reference

The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000087979

1 reference

Consolidated OpenCitations Corpus – April 2017

2704725

2704725

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference